These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

196 related items for PubMed ID: 1999494

  • 1. Acquired cisplatin resistance in human ovarian cancer cells is associated with enhanced repair of cisplatin-DNA lesions and reduced drug accumulation.
    Parker RJ, Eastman A, Bostick-Bruton F, Reed E.
    J Clin Invest; 1991 Mar; 87(3):772-7. PubMed ID: 1999494
    [Abstract] [Full Text] [Related]

  • 2. Ormaplatin sensitivity/resistance in human ovarian cancer cells made resistant to cisplatin.
    Parker RJ, Vionnet JA, Bostick-Bruton F, Reed E.
    Cancer Res; 1993 Jan 15; 53(2):242-7. PubMed ID: 8417816
    [Abstract] [Full Text] [Related]

  • 3. Role of carrier ligand in platinum resistance of human carcinoma cell lines.
    Schmidt W, Chaney SG.
    Cancer Res; 1993 Feb 15; 53(4):799-805. PubMed ID: 8428361
    [Abstract] [Full Text] [Related]

  • 4. Cellular pharmacology of liposomal cis-bis-neodecanoato-trans-R,R-1,2-diaminocyclohexaneplatinum(II) in A2780/S and A2780/PDD cells.
    Han I, Ling YH, al-Baker S, Khokhar AR, Perez-Soler R.
    Cancer Res; 1993 Oct 15; 53(20):4913-9. PubMed ID: 8402681
    [Abstract] [Full Text] [Related]

  • 5. Cisplatin-induced apoptosis proceeds by caspase-3-dependent and -independent pathways in cisplatin-resistant and -sensitive human ovarian cancer cell lines.
    Henkels KM, Turchi JJ.
    Cancer Res; 1999 Jul 01; 59(13):3077-83. PubMed ID: 10397248
    [Abstract] [Full Text] [Related]

  • 6. Enhanced cisplatin cytotoxicity by disturbing the nucleotide excision repair pathway in ovarian cancer cell lines.
    Selvakumaran M, Pisarcik DA, Bao R, Yeung AT, Hamilton TC.
    Cancer Res; 2003 Mar 15; 63(6):1311-6. PubMed ID: 12649192
    [Abstract] [Full Text] [Related]

  • 7. Transport of cisplatin and bis-acetato-ammine-dichlorocyclohexylamine Platinum(IV) (JM216) in human ovarian carcinoma cell lines: identification of a plasma membrane protein associated with cisplatin resistance.
    Sharp SY, Rogers PM, Kelland LR.
    Clin Cancer Res; 1995 Sep 15; 1(9):981-9. PubMed ID: 9816070
    [Abstract] [Full Text] [Related]

  • 8. Effect of lung resistance-related protein on the resistance to cisplatin in human ovarian cancer cell lines.
    Wang W, Ke S, Chen G, Gao Q, Wu S, Wang S, Zhou J, Yang X, Lu Y, Ma D.
    Oncol Rep; 2004 Dec 15; 12(6):1365-70. PubMed ID: 15547764
    [Abstract] [Full Text] [Related]

  • 9. Gene-specific repair of Pt/DNA lesions and induction of apoptosis by the oral platinum drug JM216 in three human ovarian carcinoma cell lines sensitive and resistant to cisplatin.
    O'Neill CF, Koberle B, Masters JR, Kelland LR.
    Br J Cancer; 1999 Dec 15; 81(8):1294-303. PubMed ID: 10604725
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Association between cisplatin resistance and mutation of p53 gene and reduced bax expression in ovarian carcinoma cell systems.
    Perego P, Giarola M, Righetti SC, Supino R, Caserini C, Delia D, Pierotti MA, Miyashita T, Reed JC, Zunino F.
    Cancer Res; 1996 Feb 01; 56(3):556-62. PubMed ID: 8564971
    [Abstract] [Full Text] [Related]

  • 13. Correlation between cell killing by cis-diamminedichloroplatinum(II) in six mammalian cell lines and binding of a cis-diamminedichloroplatinum(II)-DNA antiserum.
    Terheggen PM, Emondt JY, Floot BG, Dijkman R, Schrier PI, den Engelse L, Begg AC.
    Cancer Res; 1990 Jun 15; 50(12):3556-61. PubMed ID: 2340504
    [Abstract] [Full Text] [Related]

  • 14. Increased DNA repair as a mechanism of acquired resistance to cis-diamminedichloroplatinum (II) in human ovarian cancer cell lines.
    Masuda H, Ozols RF, Lai GM, Fojo A, Rothenberg M, Hamilton TC.
    Cancer Res; 1988 Oct 15; 48(20):5713-6. PubMed ID: 3139281
    [Abstract] [Full Text] [Related]

  • 15. The role of topotecan for extending the platinum-free interval in recurrent ovarian cancer: an in vitro model.
    Horowitz NS, Hua J, Gibb RK, Mutch DG, Herzog TJ.
    Gynecol Oncol; 2004 Jul 15; 94(1):67-73. PubMed ID: 15262121
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Alterations in the expression of the apurinic/apyrimidinic endonuclease-1/redox factor-1 (APE1/Ref-1) in human ovarian cancer and indentification of the therapeutic potential of APE1/Ref-1 inhibitor.
    Zhang Y, Wang J, Xiang D, Wang D, Xin X.
    Int J Oncol; 2009 Nov 15; 35(5):1069-79. PubMed ID: 19787261
    [Abstract] [Full Text] [Related]

  • 18. Acquired alkylating drug resistance of a human ovarian carcinoma cell line is unaffected by altered levels of pro- and anti-apoptotic proteins.
    Roy G, Horton JK, Roy R, Denning T, Mitra S, Boldogh I.
    Oncogene; 2000 Jan 06; 19(1):141-50. PubMed ID: 10644989
    [Abstract] [Full Text] [Related]

  • 19. Association between the level of ERCC-1 expression and the repair of cisplatin-induced DNA damage in human ovarian cancer cells.
    Li Q, Yu JJ, Mu C, Yunmbam MK, Slavsky D, Cross CL, Bostick-Bruton F, Reed E.
    Anticancer Res; 2000 Jan 06; 20(2A):645-52. PubMed ID: 10810335
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.